Impact of KRAS Mutation Subtype and Concurrent Pathogenic Mutations on Non-Small Cell Lung Cancer Outcomes

Activating mutations in the KRAS oncogene are the most common genetic driver in non-small cell lung cancer (NSCLC), appearing in about 25% of adenocarcinomas and 3% of squamous cell carcinomas [1,2]. Despite their prevalence, the prognostic impact of KRAS mutations remains uncertain. A pooled analysis of phase III clinical trials evaluating adjuvant chemotherapy in early-stage NSCLC determined that KRAS mutations had a negligible impact on overall survival (OS) in patients randomized to observation [3].

Source: Lung Cancer - May 14, 2019 Category: Cancer & Oncology Authors: Jacqueline V. Aredo, Sukhmani K. Padda, Christian A. Kunder, Summer S. Han, Joel W. Neal, Joseph B. Shrager, Heather A. Wakelee Source Type: research